sanofi ends Metabolex deal

sanofi-aventis Group (Euronext:SAN; NYSE:SNY) terminated a 2010 deal with Metabolex Inc. (Hayward, Calif.) and returned rights to diabetes candidate SAR260093/ MBX-2982. Metabolex said sanofi made its decision after reviewing data from a completed Phase II trial of the G protein-coupled receptor 119 (GPR119) agonist for Type II diabetes. Metabolex said the data are not public. Metabolex said it is deciding future plans for MBX-2982 (see BioCentury Extra, June 25, 2010).

sanofi also said its SSR125543, a corticotropin-releasing factor 1 (CRF1) antagonist, missed the primary endpoint in a Phase II trial to treat depression and was subsequently discontinued. ...